The inadequate biochemical control of acromegaly may be due to suboptimal dosing of medical therapies, poor compliance to treatments, resistance to drugs, tumor phenotype, inadequate monitoring, and uncertainty of GH and IGF-I assays (2). This evidence concerns the gene GH1 and neoplasm.